Clinical Trial Update: Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions [NA]

View source ↗

Summary

A completed clinical study evaluating the Cilostazol Eluting Stent System (CES-1) for de novo coronary artery lesions in coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Cilostazol Eluting Stent System (CES-1) (cilostazol)

Snippet

Sponsor: JIMRO Co., Ltd. | Conditions: Coronary Artery Disease | NA | Status: COMPLETED